Unibest

Pharmaceutical intermediates

Suvorexant Intermediates

5 pharmaceutical intermediates for Suvorexant. Indication: Sleep Initiation and Maintenance Disorders.

提交项目All intermediates

About Suvorexant

Originator
Merck Sharp And Dohme Llc
Indication
Sleep Initiation and Maintenance Disorders
Approved Date
08/13/2014
DS/DP
11/20/2029

Available intermediates

5 intermediates currently listed for Suvorexant. Request specifications, documentation or a quotation for any item below.

Suvorexant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1H-1,4-Diazepine-1-carboxylic acid, hexahydro-5-Methyl-, phenylMethyl ester, (5R)-1001401-60-0//
2,5-Dichlorobenzooxazole3621-81-6//
(R)-1-benzyl-5-methyl-1,4-diazepane1620097-06-4//
1,2,3-1H-Triazole288-36-8//
5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid956317-36-5//

Other programs under S

SaracatinibSarecycline HydrochlorideSarolanerSaxagliptinSeladelparSeltorexantSemaglutideSitafloxacin hydrate

Building toward Suvorexant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →